Praesidium Investment Management Company LLC Boosts Stake in Cellebrite DI Ltd. $CLBT

Praesidium Investment Management Company LLC boosted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 339.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,185,274 shares of the company’s stock after acquiring an additional 915,821 shares during the period. Cellebrite DI comprises 4.0% of Praesidium Investment Management Company LLC’s investment portfolio, making the stock its 9th largest position. Praesidium Investment Management Company LLC’s holdings in Cellebrite DI were worth $21,370,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Norwood Investment Partners LP bought a new position in Cellebrite DI during the 3rd quarter worth $4,274,000. TimesSquare Capital Management LLC bought a new position in Cellebrite DI during the 3rd quarter worth $11,217,000. Wisconsin Capital Management LLC bought a new position in Cellebrite DI during the 3rd quarter worth $1,649,000. Portolan Capital Management LLC increased its stake in Cellebrite DI by 139.1% during the 3rd quarter. Portolan Capital Management LLC now owns 2,419,662 shares of the company’s stock worth $44,836,000 after acquiring an additional 1,407,818 shares during the period. Finally, King Luther Capital Management Corp bought a new position in Cellebrite DI during the 3rd quarter worth $5,582,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $12.84 on Friday. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98. The company has a market cap of $3.20 billion, a price-to-earnings ratio of 45.86, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. The business’s fifty day moving average is $13.23 and its 200 day moving average is $15.05.

Insider Buying and Selling at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 13,269 shares of company stock worth $169,592. Company insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CLBT shares. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. DA Davidson started coverage on Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Needham & Company LLC reduced their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.